Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Systematic Review, Meta-Analysis, and Public Policy Implications

Supplementary Appendix

Andrew T. Levin, Gideon Meyerowitz-Katz, Nana Owusu-Boaitey, Kensington B. Cochran, and Seamus P. Walsh

14 August 2020

Appendix A: List of Excluded Studies

A.1 Studies Excluded due to Absence of Age-Specific Prevalence or Fatality Data

Location	Description
Blaine County, Idaho, USA ¹	This study collected samples from 972 individuals on May 4-19 and found an IgG prevalence of 22.7% (CI: 20–25.5%). The authors concluded that "the small number of county deaths (<i>n</i> =5) makes estimating the infection fatality rate unreliable." No age-specific fatality data is publicly available for this county.
British Columbia, Canada ²	This study analyzed 885 laboratory specimens from outpatient clinics for the period May 15-27 and found only four positive cases (0.6%). No age-specific prevalence was reported.
Chelsea, Massachusetts, USA ³	According to local media reports, this study collected specimens at a street corner on April 14 from 200 pedestrians who agreed to participate and obtained 64 positive results. No further details had been released as of August 7.
Connecticut, USA ⁴	This study analyzed specimens from a random sample of 505 adults residing in non-congregate settings. The sample design reflected the assumption of statewide prevalence of 10% (roughly similar to that of the neighboring state of New York) with the aim of obtaining prevalence estimates with precision of 2% at a confidence level of 90%. However, the study obtained a much lower estimated prevalence of 3.1% (95% CI: 1.1–5.1%). Consequently, the sample size proved to be insufficient to provide reliable age-specific results; the margin of error exceeds the estimated prevalence for all age groups reported in the study.
Czech Republic⁵	The Czech Ministry of Health conducted a large-scale seroprevalence survey on April 23-May 1, collecting specimens from a random sample of 22,316 residents and testing for IgG antibodies using the Wantai test kit. Only 107 positive cases were identified (raw prevalence = 0.4%), and hence the test-adjusted confidence intervals include the lower bound of zero prevalence. That result is consistent with the very low number of reported cases in the Czech Republic as of early May; for example, Prague had only 1,638 reported cases for a population of 1.3 million.
Denmark ⁶	This study analyzed specimens from a random sample of 1,071 individuals tested on June 9 and identified 12 positive cases, yielding a seroprevalence of 1.2% (CI: 0.7–1.7%). Age-specific estimates have not been reported as of August 1 but would likely be imprecise due to the sample size and low prevalence.
Faroe Islands Denmark ⁷	This study analyzed specimens from a random sample of 1,075 participants during late April and obtained 6 positive results; the test-adjusted prevalence was 0.7% (CI: 0.3–1.3%). No age-specific results were reported.
Gangelt, Germany ⁸	This study analyzed specimens from a random sample of 919 participants from the municipality of Gangelt (population 12,597) on March 31 to April 6 and obained a test-adjusted prevalence of 15.5% (CI: 12.3–19.0%). Official government reports indicate that Gangelt had 7 COVID-19 fatalities at the time of the study but the death toll rose to 12 by late June, indicating an overall IFR of about 0.6%, similar to the IFR for Geneva. Age-specific fatalities are not reported for Gangelt.
Hermiston, Oregon ⁹	Field teams canvassed neighborhoods and collected samples from 471 individuals and obtained 41 positive results (test-adjusted seroprevalence of 1.7%); no confidence intervals or age-specific results have been reported as of August 1.

Ischgl, Austria ¹⁰	This study analyzed specimens from 184 adults in Ischgl (an Austrian municipality of 1,604 residents) and obtained 85 positive results, i.e., prevalence of 46.2%. The study reported the fraction of positive results for specific age groups (4 out of 11 adults 55-64 years, 2 out of 8 adults 65-74 years, and 1 out of 2 adults ages 75+) but did not report test-adjusted estimates or confidence intervals by age group. Ischgl had only 2 reported COVID-19 fatalities as of July 1.
Japanese Evacuees ¹¹	This study performed PCR tests on 565 Japanese citizens expatriated from Wuhan, China. There were eight positive tests, indicating a raw prevalence of 1.4%, but assessment of age-specific prevalence or IFRs is not feasible given the small sample, low prevalence, and lack of data on case outcomes.
Jersey, United Kingdom ¹²	This study collected samples from 629 households comprising 1,062 individuals and estimated seroprevalence at 4.2% (CI 2.9 to 5.5%), indicating that about 3,300 Jersey residents have been infected. Jersey has had 30 COVID-19 fatalities (as of July 15), and hence the overall IFR is about 1% (similar to that of NYC). However, the seroprevalence sample is too small to facilitate accurate assessments of age-specific IFRs; for ages 55+, there were 258 samples and 12 positive cases,
Miami-Dade County, Florida, USA ¹³	This study analyzed samples from 2,357 individuals in April and obtained 65 positive IgG results; an additional 275 individuals were tested in June with 4 positive results. Test-adjusted seroprevalence estimates and confidence intervals have not been published as of August 7.
New York City, New York, USA ¹⁴	This study analyzed seroprevalence using specimens from four groups of patients (Cardiology, OB/GYN, Oncology, and Surgery) starting in mid-February. For the final week of the study (April 19), positive results were obtained for 47 of 243 patients; that seroprevalence estimate of 19.3% is well-aligned with the results of the New York Department of Health study. However, the sample size of this cohort is too small for assessing age-specific IFRs.
Neustadt-am-Rennsteig, Germany ¹⁵	This study analyzed seroprevalence of 626 residents (71% of the population of this municipality) and estimated seroprevalence of 8.4% (52 positive cases). However, this sample size is too small for assessing age-specific IFRs.
New Orleans, Louisiana, USA ¹⁶	This study analyzed seroprevalence in a random sample of 2,640 participants and obtained a seroprevalence estimate of 6.9% and an IFR of 1.6% (CI 1.5 to 1.7%). The study did not report on age-specific seroprevalence or IFRs.
Norbotten, Sweden ¹⁷	This study analyzed a randomly-selected sample of 425 adults and obtained 8 positive results; the test-adjusted seroprevalence was 1.9% (CI: 0.8–3.7%). However, only 2 positive results were for ages 30-64 and 2 positive results for ages 65+, so age-specific prevalence and IFRs cannot be reliably estimated.
Occitania, France ¹⁸	This study analyzed samples from 613 individuals "who were exposed to the virus to varying extents mimicking the general population in Occitania" and found seroprevalence of 1.3% (CI: 0.6–2.6%). The study does not report any age-specific data.
Oklahoma, USA ¹⁹	The Oklahoma Department of Health publishes weekly data on raw seroprevalence using samples collected from labs within the state, but its reports do not include test-adjusted estimates, confidence intervals, or age-specific results.

Oslo, Norway ²⁰	This study used specimens from 397 participants in the Norwegian Mother, Father and Child Survey (MoBa) and found seroprevalence of "less than 2 percent." No confidence intervals or age-specific results were reported.
Rhode Island, USA ²¹	This study invited 5000 randomly-selected households, collected samples from "roughly 10 to 15 percent" who agreed to participate, and obtained seroprevalence of 2.2% (CI: 1.1–3.9%). No age-specific results have been reported as of August 1.
Riverside County, California, USA ²²	This study tested a randomized sample of 1,726 residents during July and found raw seroprevalence of 5.9%. The press release (issued on July 27) indicated that the results "are still being analyzed"; no test-adjusted seroprevalence results or age-specific findings have been reported as of August 1.
San Francisco Mission District, California ²³	This study analyzed active infections and seroprevalence of 3,953 residents in a densely population majority Latinx neighborhood in downtown San Francisco. Positive seroprevalence in older adults was very low (22 out of 3,953) and hence too small for assessing age-specific IFRs.
San Miguel County, Colorado, USA ²⁴	The San Miguel County Health Department assessed seroprevalence in March and April using samples from 5,283 participants (66% of county residents). Raw prevalence was very low (0.53%), with only 3 confirmed positive results for adults ages 60 years and above.
Slovenia ²⁵	Researchers at the University of Ljubljana assessed seroprevalence using an IgG ELISA test for a random sample of 1,318 participants on April 20 to May 3. Test-adjusted prevalence was 0.9% (CI: 0 to 2.1%), indicating that the sample may have included only 10 infected individuals; no age-specific results were reported.
South-East England ²⁶	This study collected samples from 481 participants of the TwinsUK cohort and obtained 51 positive results (raw prevalence of 12%). No age-specific results were reported.
Stockholm, Sweden ²⁷	This study did not directly assess prevalence but produced estimates of IFR for two age groups (ages 0-69 and 70+) using a novel methodology linking live virus tests, reported cases, and mortality outcomes. The estimated IFR was 4.3% for ages 70+.
Stockholm Region, Sweden ²⁸	Stockholm County began offering antibody testing on a free walk-up basis. As of July 20, 166,431 antibody tests had been performed, of which 17.7% were positive. No demographic data or test-adjusted seroprevalence results had been reported as of August 7.
Miyagi, Osaka, and Tokyo, Japan ²⁹	This study collected samples from randomly-selected residents of three cities on June 1-7 and used two IgG test kits (Abbott and Roche); results were deemed "positive" only if confirmed by both tests Estimated seroprevalence was 0.1% in Tokyo (2 positive results from 1,971 specimens), 0.17% in Osaka (5 positive results from 2,970 specimens), and 0.03% in Miyagi (1 positive result from 3,009 specimens). No age-specific prevalence estimates were reported.
United States ³⁰	Seroprevalence estimates are reported in the U.S. CDC's weekly COVID-19 surveillance summary using data collected by 85 state and local public health laboratories. These reports include age-specific seroprevalence but no details regarding sample selection, test characteristics, or confidence intervals and hence could not be used in our metaregression.

Г

Utsunomiya, Japan ³¹	This study tested a random sample of 742 participants and found 3 confirmed positive results among 463 adults ages 18 to 65 years; the test-adjusted prevalence for that age group was 0.65% (CI: 0.13% to1.8%). No positive results were obtained for the sample of 181 adults ages 65+ years.
United Kingdom ³²	The U.K. Office for National Statistics reports aggregate estimates of seroprevalence from specimens provided for routine testing using a novel IgG ELISA test conducted by research staff at the University of Oxford, but these reports do not include age-specific seroprevalence estimates.
Vo, Italy ³³	Vo' is a municipality of 3,300 people, nearly all of whom (87%) participated in an infection survey in late February. However, there were only 54 infections among people ages 50+, so assessing age-specific IFRs is not feasible.
Washoe County, Nevada, USA ³⁴	This study collected samples from 234 individuals on June 9-10 and obtained 5 positive IgG results. No age-specific results were reported.

A.2: Studies Excluded Due to Accelerating Outbreak

		Cumulative fatali	ties in thousands	Change
Location	Date	Study midpoint	4 weeks later	(%)
Los Angeles, California, USA ³⁵	April 10-11	0.265	1.468	454
New York City, New York, USA ³⁶	March 23-April 1	1.066	14.261	1238

A.3 Studies Excluded Due to Non-Representative Samples

(a) Hospitals and Urgent Care Clinics

Location	Description
Brooklyn, New York, USA ³⁷	This study used samples from an outpatient clinic and yielded a much higher infection rate than other seroprevalence studies of the New York metropolitan area.
Kobe, Japan ³⁸	This study tested for IgG antibodies in 1,000 specimens from an outpatient clinic and found 33 positive cases. However, the study did not screen out samples from patients who were seeking treatment for COVID-related symptoms. Moreover, the study reported raw prevalence and confidence interval but did not report statistics adjusted for test characteristics. The manufacturer (ADS Biotec / Kurabo Japan) has indicated that this test has specificity of 100%, based on a sample of 14 pre-COVID specimens, but that specificity has not been evaluated by any independent study. If the true specificity is 98%, then the adjusted prevalence would not be significant. The authors concluded by noting the selection bias and recommended that <i>"further serological studies targeting randomly selected people in Kobe City could clarify this potential limitation."</i>

Tokyo, Japan ^{39,40}	The authors of this study specifically cautioned against interpreting their results as representative of the general population. In particular, the sample of 1,071 participants included 175 healthcare workers, 332 individuals who had experienced a fever in the past four months, 45 individuals who had previously taken a PCR test, and 9 people living with a COVID-positive cohabitant. The study obtained a raw infection rate of 3.8%, but the rate is only 0.8% if those subgroups are excluded.
Zurich, Switzerland ⁴¹	This study analyzed two distinct set of samples: (i) blood donors and (ii) hospital patients. Nearly all blood donors were ages 20 to 55, so that sample is not useful for assessing age-specific IFRs for older adults. The sample of hospital patients was not screened to eliminate cases directly related to COVID-19, so that sample may not be representative of the broader population. Moreover, inhabitants of the city of Zurich constituted a relatively large fraction of seropositive results compared to residents from the remainder of the canton of Zurich (which is predominantly rural). The study computes an overall IFR of 0.5%, similar to that of Geneva.

(b) Studies of Blood Donors

Location	Description
Apulia, Italy ⁴²	This study assessed specimens from a sample of 904 healthy blood donors at a transfusion center in southeastern Italy and obtained 9 positive results (0.99%).
Denmark ⁴³	This study assessed specimens from a sample of 20640 Danish blood donors and calculated a test-adjusted prevalence of 1.9% (CI: $0.8-2.3$). Unfortunately, the antibody test used in this study was subsequently identified as unreliable, and the Danish government returned all remaining test kits to the manufacturer. ⁴⁴
England	Public Health England has conducted ongoing surveillance of seroprevalence using specimens from healthy adult blood donors. For example, in 7694 samples tested during May (weeks 18-21), the test-adjusted prevalence was 8.5% (CI: 6.9–10%).
Germany ⁴⁵	This study assessed residue sera from 3186 regular blood donors collected during March 9–June 3 and obtained 29 positive results (raw prevalence 0.9%). The authors stated: "It should be emphasized that the preselection of blood donors as a study cohort is accompanied by limitations regarding representation of population."
Lombardy, Italy ⁴⁶	This study assessed specimens from 390 blood donors residing in the Lodi red zone collected on April 6 and found a raw seroprevalence rate of 23%.
Milan, Italy ⁴⁷	This study assessed specimens from a random sample of 789 blood donors over the period from February 24 (at the start of the outbreak) to April 8.
Netherlands ⁴⁸	This study assessed specimens from 7361 adult blood donors collected on April 1-15 and found seroprevalence of 2.7%.
Rhode Island, USA ⁴⁹	This study assessed specimens from 2008 blood donors collected during April 27–May 11 and found seroprevalence of 0.6%.

Scotland ⁵⁰	This study assessed specimens from 3500 blood donors collected between March 17 and May 19. The authors noted that the resulting estimates of seroprevalence "are complicated by non-uniform samplingbased on the locations where weekly donations took place[and] further confounded by the absence of samples from individuals below age 18 and individuals over age 75."
San Francisco, California, USA ⁵¹	This study assessed specimens from 1000 blood donors that were collected during March and found one positive result (raw prevalence 0.1%).

(c) Active Recruitment of Participants

Location	Description
Luxembourg ⁵²	Of the 35 participants who tested positive, 19 had previously interacted with a person who was known to be infected or had a prior test for SARS-CoV-2.
Boise, Idaho ⁵³	This study was promoted during a "Crush the Curve" publicity campaign and required participants to sign up for a test.
Santa Clara, California, USA ⁵⁴	Participants were recruited via social media and needed to drive to the testing site. Stanford Medicine subsequently released a statement indicating that the study was under review due to concerns about potential biases. ⁵⁵
Frankfurt, Germany ⁵⁶	This study was conducted at a industrial worksite. Among the 5 seropositive participants, 3 had prior positive tests or direct contact with a known positive case.

(d) Other Sample Selection Issues

Location	ion Description	
Oisie, France ⁵⁷	This sample of 1,340 participants included elementary school teachers, pupils, and their families. Only two individuals in the sample were ages 65 years and above.	
Saxony, Germany ⁵⁸	This study analyzed specimen samples from students and teachers at thirteen secondary schools in eastern Saxony and found very low seroprevalence (0.6%).	

A.4 Locations Excluded from Metaregression due to Overlapping Geographical Areas

Location	Description
	This study assessed seroprevalence in a random sample of 509 residents
	of the municipality of Castiglione d'Adda, the location of the first COVID-related
Castiglione d'Adda,	fatality in Italy. Specimens were collected on May 18–25. Seroprevalence
Italy ⁵⁹	was estimated at 22.6% (CI: 17.2–29.1%). This study is included in our
	meta-analysis but not in our metaregression because this municipality is covered
	by a nationwide seroprevalence study of Italy. ⁶⁰
	This ship was carrying 3,711 passengers and crew; its demographic composition was
	not necessarily representative of any specific geographical location. RT-PCR tests
Diamond Princess	indicated that 619 individuals had been infected prior to the ship's dembarkation
Cruise Ship ⁶¹	on March 7, and 14 individuals subsequently died due to COVID-related causes.
	The IFR was 0.5% for ages 60-69, 2.9% for ages 70-79, and 7.9% for ages 80+,
	broadly consistent with the metaregression results of this study.
Great Britain ⁶²	This study assessed seroprevalence using specimens collected from a demographically balanced panel of 17,776 participants on May 27 to July 6. Our metaregression includes a much larger seroprevalence study of the English population. ⁶³ Consequently, this study is included in our meta-analysis but not in our metaregression to avoid pitfalls of nested or overlapping samples.
Utah, USA ³⁶	This study analyzed commercial lab specimens from 1132 individuals collected during April 20–May 3. This study is not included in our meta-analysis because a subsequent sudy analyzed a much larger randomized sample of 6527 residents of the Salt Lake City metropolitan area during May 4–June 10. ⁶⁴ As of May, that metro area accounted for nearly 90% of COVID-related fatalities in Utah.

A.5 Exclusion of Observations with Statistically Insignificant Seroprevalence

		95% Confidence Interval (%)		
Location	Age Group	Prevalence (%)	Lower Bound	Upper Bound
Atlanta, Georgia, USA	65+	0.7	0.1	4.5
Minneapolis,	50–59	0.7	0	2.8
Minnesota, USA	60+	1.0	0	3.2
Philadelphia,	50–64	0.8	0	2.8
Pennsylvania, USA	65+	1.6	0.3	3.5
Salt Lake City, Utah, USA	65+	0.6	0	1.4
San Francisco,	19–49	1.1	0	2.6
California, USA	50–64	0.7	0	2.4

Note: Table A.5 shows observations with median age of 35 years or above for which either

(a) the lower bound of the 95% confidence interval equals zero, and hence the upper bound of the IFR is not well defined; or (b) the lower bound of the 95% confidence interval is less than the observed COVID-19 mortality rate for that age group, implying an upper bound

for the IFR that exceeds 100%.

Appendix B: Positive Predictive Value of Seroprevalence Tests

A key metric of test reliability is positive predictive value (PPV), that is, the likelihood that a positive test result is a true positive. The PPV can be evaluated as follows:

$$PPV = \frac{\text{sensitivity} \times \text{prevalence}}{\text{sensitivity} \times \text{prevalence} + (1 - \text{specificity}) \times (1 - \text{prevalence})}$$

Evidently, lower prevalence can markedly diminish the reliability of seroprevalence testing. As shown in Table B1, in a seroprevalence study of Dutch blood donors using the Wantai Total Antibody ELISA, the crude prevalence rate was found to be 2.7%.¹ However, that antibody test has a PPV of 42.4%, and hence the adjusted prevalence is only 0.6%, with a 95% confidence interval of 0–5.2%. In effect, *practically all of the positive tests obtained in this study might be false positives*. By contrast, a seroprevalence study of New York City found a much higher crude prevalence of 20.0% using a Wadsworth Pan-Ig test with a PPV of 94.8%.² Consequently, the adjusted prevalence for this study is *higher* than the crude prevalence, namely, 21.7% with a 95% confidence interval of 19.2–24.4%.

Location	Netherlands				New York City		
Crude Prevalence		2.7%		20%			
Test	Wantai Total Antibody ELISA			Wadsworth Pan-Ig			
		95% Confid	ence Bounds		95 % Confidence Bounds		
	Mean	Lower	Upper	Mean	Lower	Upper	
Sensitivity	0.621	0.520	0.720	0.880	0.805	0.928	
Specificity	0.977	0.950	1.000	0.988	0.973	0.995	
PPV	0.424	0.224	1.000	0.948	0.882	0.979	
NPV	0.989	0.986	0.992	0.971	0.952	0.982	
Adjusted Prevalence	0.006	0.000	0.052	0.217	0.192	0.244	

Table B1: Impact of Crude Prevalence on Positive Predictive Value

¹ See Slot et al. (2020)

² See Rosenberg et al. (2020).

Test sensitivity and specificity also have a high impact on PPV. As shown in Table B2, a serological study of Santa Clara County utilized a Premier Biotech LFA test and estimated prevalence at 1.5% based on a test specificity of 99.5%.³ However, a subsequent study found the specificity of that test to be only 97.2%.⁴ That revision to the test specificity reduces its PPV in the context of the Santa Clara study to 31.1% (less than half of the PPV assumed by the authors), and hence the adjusted prevalence is not significantly greater than zero.

Location	Santa Clara County					
Crude Prevalence	1.5%					
Test	Premier Biotech LFA					
Source		Bendavid et al	•		Whitman	et al.
		95% Confide	ence Bounds		95 % Confidence Bounds	
	Mean	Lower	Upper	Mean	Lower	Upper
Sensitivity	0.828	0.760	0.884	0.828	0.760	0.884
Specificity	0.995	0.992	0.997	0.972	0.921	0.994
PPV	0.716	0.591	0.818	0.311	0.128	0.692
NPV	0.997	0.996	0.998	0.997	0.996	0.998
Adjusted Prevalence	0.012	0.009	0.014	0.000	0.000	0.010

 Table B2: Impact of Specificity on Positive Predictive Value

³ See Bendavid et al. (2020).

⁴ See Whitman et al. (2020).

Appendix C: Excess Mortality

In some locations, reported deaths may not fully capture all fatalities resulting from COVID-19 infections, especially when a large fraction of such deaths occur outside of medical institutions. In the absence of accurate COVID-19 death counts, *excess mortality* can be computed by comparing the number of deaths for a given time period in 2020 to the average number of deaths over the comparable time period in prior calendar years, e.g., 2015 to 2019. This approach has been used to conduct systematic analysis of excess mortality in European countries.⁵ Likewise, the U.S. Center for Disease Control & Prevention provides regular updates on excess mortality for U.S. geographical locations.⁶

The Belgian study used in our benchmark analysis computed age-specific IFRs using seroprevalence findings in conjunction with data on excess mortality in Belgium. In that case, the authors noted that their measure of excess mortality over the period from March to May coincided almost exactly with Belgium's tally of reported COVID-19 cases.⁷ Consequently, we follow a parallel approach in constructing age-specific IFRs for Spain, using the seroprevalence findings of that national study in conjunction with age-specific measures of excess mortality published by Spain National Institute for Statistics.⁸

Age	Reported	Estimated	Confidenc	e Interval	Ratio of Infections	Confidence Interval	
Group	Cases	Infections	Lower	Upper	to Reported Cases	Lower	Upper
30-39	289	469	469	703	1.6	1.6	2.4
40-49	357	644	473	859	1.8	1.3	2.4
50-59	306	337	211	547	1.1	0.7	1.8
60-69	213	225	188	375	1.1	0.9	1.8
70-79	63	70	63	304	1.1	1.0	4.8
80+	25	26	13	319	1.0	0.5	12.8
All 30+	1,253	1,771	1,415	3,109	1.41	1.13	2.48

Appendix D: Comparison of Seroprevalence vs. Reported Cases in Iceland

Sources: cases are reported by Iceland Directorate of Health (2020) as of June 14, when Iceland had 1,796 recovered cases, 10 fatalities, and 4 individuals in isolation (none hospitalized). Estimated infections and 95% confidence intervals are taken from the seroprevalence study of Gujbjartsson et al. (2020).

⁵ See EuroMoMo (2020).

⁶ See Rinaldi and Paradisi (2020), Modi et al. (2020), and U.S. Center for Disease Control & Prevention (2020c).

⁷ See Molenberghs et al. (2020).

⁸ See Pollán et al. (2020) and Spain National Institute of Statistics (2020).

Appendix E: Comorbidities

	NYC	NYC	
	Hospitalized	Population	
Comorbidity	COVID Patients	(Ages 50+)	Difference
Cancer	5.6%	6.3%	-0.7%
Cardiovascular Disease			
Hypertension	53.1%	49.2%	3.9%
Coronary artery disease	10.4%	10.5%	-0.1%
Congestive heart failure	6.5%	6.9%	-0.4%
Chronic Respiratory Disease			
Asthma	8.4%	8.6%	-0.2%
Chronic obstructive pulmonary			
disease	5.0%	7.7%	-2.7%
Obstructive sleep apnea	2.7%	2.8%	-0.1%
Immunosuppression			
HIV	0.8%	2.7%	-2.0%
History of solid organ transplant	1.0%	NA	NA
Kidney Disease			
Chronic	4.7%	13.1%	-8.4%
End-Stage	3.3%	0.6%	2.6%
Liver Disease			
Cirrhosis	0.3%	0.9%	-0.6%
Hepatitis B	0.1%	0.5%	-0.3%
Hepatitis C	0.1%	0.1%	0.0%
Metabolic Disease			
Obesity (BMI>=30)	41.7%	26.9%	14.8%
Diabetes	31.7%	27.6%	4.1%
Ever Smoked	15.6%	43.8%	-28.2%

Table E1: Comorbidity Prevalence in New York City (NYC)Hospitalized COVID-19 Patients vs. General Population

Note: The following sources were used to gauge the prevalence of comorbidities among NYC residents ages 50 years and above. *Asthma*: U.S. Center for Disease Control & Prevention (2018). *Cancer*: New York State Cancer Registry (2016). *Cardiovascular Diseases*: New York Department of Health (2020). *Diabetes*: New York State Comptroller (2015). *HIV*: New York City Department of Health (2018). *Kidney Disease*: IPRO End-Stage Renal Disease Network of New York (2014). *Liver Disease*: Moon et al. (2019) and Must et al. (1999). *Chronic Pulmonary Disease*: New York Department of Health (2019). *Obesity*: New York City Department of Health (2019).

Age	Hazard Ratio	Comorbidity	Hazard Ratio
20 to 49	1	Diabetes	1.1
50 to 59	2.7	Malignant Cancer	1.1
60 to 69	5.5	Chronic Cardiac Disease	1.2
70 to 79	9.8	Chronic Pulmonary Disease	1.2
80+	13.5	Chronic Kidney Disease	1.3
		Obesity	1.3
		Liver Disease	1.5

 Table E2: Fatality Hazard Ratios for Hospitalized U.K. COVID-19 Patients

Source: Doherty et al. (2020), Figure 5.

References

- 1 McLaughlin CC, Doll MK, Morrison KT, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *medRxiv* 2020.
- 2 Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. 2020.
- 3 Saltzman J. Nearly a third of 200 blood samples taken in Chelsea show exposure to coronavirus. Boston Globe. 2020 4/17/2020.
- 4 Mahajan S, Srinivasan R, Redlich CA, et al. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut Between March 1 and June 1, 2020: Post-Infection Prevalence (PIP) Study. *medRxiv* 2020: 2020.08.04.20168203.
- 5 Czech Ministry of Health. Collective Immunity Study SARS-CoV-2: Czech Prevalence. 2020.
- 6 Denmark State Blood Institute. Notat: Nye foreløbige resultater fra den repræsentative seroprævalensundersøgelse af COVID-19. 2020.
- 7 Petersen MS, Strøm M, Christiansen DH, et al. Seroprevalence of SARS-CoV-2–Specific Antibodies, Faroe Islands. *emerging infectious diseases* 2020; **26**(11).
- 8 Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. 2020.
- 9 Oregon State University. TRACE results suggest 17% of Hermiston community infected with SARS-CoV-2. 2020.
- 10 von Laer D. U.S. National Institutes of Health COVID-19 lecture: high seroprevalence, drastic decline of incidence, and low infection fatality rate of SARS-CoV-2 infections in children and adults in the ski resort Ischgl, Austria. 2020.
- 11 Nishiura H, Kobayashi T, Yang Y, et al. The Rate of Underascertainment of Novel Coronavirus (2019nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights. *J Clin Med* 2020; **9**(2).
- 12 Jersey Health & Community Services. Prevalence of Antibodies Community Survey Round 2. 2020.
- 13 University of Miami. SPARK-C: understanding the burden of COVID-19 in Miami-Dade County through rapid serological testing of a representative random sample. 2020.
- 14 Stadlbauer D, Tan J, Jiang K, et al. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. *medRxiv* 2020: 2020.06.28.20142190.
- 15 Weis S, Scherag A, Baier M, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak the CoNAN study. 2020.
- 16 Feehan AK, Fort D, Garcia-Diaz J, et al. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. *Emerg Infect Dis* 2020; **26**(11).
- 17 Norrbotten Region. Forekomst av antikroppar mot covid-19 Norrbottens befolkning maj 2020. 2020.
- 18 Dimeglio C, Loubes J-M, Miedougé M, Herin F, Soulat J-M, Izopet J. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. Research Square; 2020.
- 19 Oklahoma State Department of Health. Weekly Epidemiology and Surveillance Report. 2020.
- 20 Norway Public Health Institute. Truleg berre ein liten andel av befolkninga som har vore smitta av koronavirus. 2020.
- 21 Rhode Island Department of Health. COVID-19 serology testing brief. 2020.
- 22 Riverside County Joint Information Center. Antibody study shows coronavirus spread wider in Riverside County. 2020.
- 23 Chamie G, Marquez C, Crawford E, et al. SARS-CoV-2 Community Transmission During Shelter-in-Place in San Francisco. 2020.
- 24 San Miguel County Department of Health & Environment. IgG Antibody Tests: Statistics and Demographics. 2020.
- 25 Slovenia Government Communication Office. First study carried out on herd immunity of the population in the whole territory of Slovenia. 2020.

- 26 Wells PM, Doores KM, Couvreur S, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. 2020.
- 27 Sweden Public Health Authority. The Infection Fatality Rate of COVID-19 in Stockholm Technical Report. 2020.
- 28 Stockholm Region. Lägesrapport om arbetet med det nya coronaviruset. 2020.
- 29 Japan Ministry of Health Labour and Welfare. Updates on COVID-19 in Japan. 2020.
- 30 U.S. Center for Disease Control and Prevention. COVIDView weekly report U.S. virologic surveillance by public health laboratories. 2020.
- Nawa N, Kuramochi J, Sonoda S, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City,
 Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study.
 2020.
- 32 United Kingdom Office for National Statistics. Coronavirus (COVID-19) Infection Survey Pilot. 2020.
- 33 Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. 2020.
- 34 Washoe County Health District. Seroprevalence of SARS-CoV-2 Specific Antibodies Among Adults in Washoe County, Nevada on June 9-10, 2020. 2020.
- 35 Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA* 2020.
- 36 Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med* 2020.
- 37 Reifer J, Hayum N, Heszkel B, Klagsbald I, Streva VA. SARS-CoV-2 IgG antibody responses in New York City. *diagnostic microbiology and infectious disease* 2020.
- 38 Doi A, Iwata K, Kuroda H, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study. 2020.
- 39 Takita M, Matsumura T, Yamamoto K, et al. Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing. *J Prim Care Community Health* 2020; **11**: 2150132720942695.
- 40 Takita M, Matsumura T, Yamamoto K, et al. Challenges of community point-of-care antibody testing for COVID-19 herd-immunity in Japan. *QJM* 2020.
- 41 Emmenegger M, Cecco ED, Lamparter D, et al. Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay. 2020.
- 42 Fiore J, Centra M, de Carlo A, et al. Far away from herd immunity to SARS-CoV-2: results from a survey in healthy blood donors in southeastern Italy. 2020.
- 43 Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. *clinical infectious diseases* 2020.
- 44 Reuters Health News. Denmark to send back inaccurate antibody tests from China's Livzon. 2020 May 20.
- 45 Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. *Euro Surveill* 2020; **25**(28).
- 46 Percivalle E, Cambie G, Cassaniti I, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. *Euro Surveill* 2020; **25**(24).
- 47 Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. 2020.
- 48 Slot E, Hogema BM, Reusken CBEM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. 2020.
- 49 Nesbitt DJ, Jin D, Hogan JW, et al. Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats. 2020.
- 50 Thompson CP, Grayson N, Paton R, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020. *medRxiv* 2020: 2020.04.13.20060467.

- 51 Ng D, Goldgof G, Shy B, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. *medRxiv* 2020.
- 52 Snoeck CJ, Vaillant M, Abdelrahman T, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. 2020.
- 53 Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 2020; **58**(8).
- 54 Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. 2020.
- 55 Kekatos M. Stanford University is investigating its own researchers over claims their antibody study was politically motivated and 'tipped the scale' to make COVID-19 seem less lethal. Daily Mail. 2020 May 26.
- 56 Kraehling V, Kern M, Halwe S, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. 2020.
- 57 Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. *medRxiv* 2020: 2020.04.18.20071134.
- 58 Armann JP, Unrath M, Kirsten C, Lueck C, Dalpke A, Berner R. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates. 2020.
- 59 Pagani G, Conti F, Giacomelli A, et al. Seroprevalence of SARS-CoV-2 IgG significantly varies with age: results from a mass population screening (SARS-2-SCREEN-CdA). 2020.
- 60 Italy National Institute of Statistics. Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2. 2020.
- 61 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *eurosurveillance* 2020; **25**(10).
- 62 United Kingdom BioBank. UK Biobank SARS-CoV-2 Serology Study Weekly Report 21 July 2020. 2020.
- 63 Ward H, Atchison C, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. 2020.
- 64 University of Utah Health. Utah HERO project announces phase one findings. 2020.